Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Stat family:stat 3 in skin disorders by yousry


Published on

the role of stat proteins in cells signaling pathways.Stat 3 protein in immunopathogenesis of psoriasis.ppt

Published in: Health & Medicine
  • Be the first to comment

Stat family:stat 3 in skin disorders by yousry

  1. 1. Signal Transducers &Activators of Transcription( STAT) Family:Role of Stat 3 in Skin Disorders <ul><li>DR M.YOUSRY ABDEL-MAWLA,MD </li></ul><ul><li>ZAGAZIG FACULTY OF MEDICINE,EGYPT </li></ul>
  3. 3. Signal transducers and activators of transcription ) Stat) Family <ul><li>Stats are latent in the cytoplasm until they are activated by extracellular signaling ligands , including cytokines , growth factors and hormones. </li></ul><ul><li>Binding of these extracellular ligands to the specific receptors leads to activation of various tyrosine kinases (TKs). </li></ul><ul><li>They include JAKs, receptor TKs, and non-receptor TKs such as Src and ABL, which can directly phosphorylate Stat proteins in the absence of ligand-induced receptor signaling </li></ul>
  4. 4. NK-22 cell-secreted cytokines stimulate epithelial cells to proliferate, release IL-10 and activate STAT1 and STAT3. M Cella et al. Nature 000, 1-4 (2008)
  5. 6. CYTOKINES, CYTOKINE RECEPTORS, ACTIVATED SIGNALING MOLECULES AND MAJOR BIOLOGICAL FUNCTIONS <ul><li>Cytokines receptor signaling molecules biological function </li></ul><ul><li>IL-2 IL-2R Jak1/3, Stat5/3 T cell growth and peripheral tolerance; NK activity; B cell differentiation </li></ul><ul><li>IL-4 IL-4R Jak1/3, Stat6 Th2 differentiation; B cell differentiation </li></ul><ul><li>IL-7 IL-7R Jak1/3,sata5/3 T-cell homeostasis; T and B development (mouse) </li></ul><ul><li>IL-9 IL-9R Jak1/3, Stat5/3 Airway mucus production; mast cell proliferation </li></ul><ul><li>IL-15 IL-15R Jak1/3, Stat5/3 CD8 homeostasis, NK cell development </li></ul><ul><li>IL-21 IL-21R Jak1/3, Stat3,5,1 B-cell differentiation; T and NK activation </li></ul>
  6. 8. STAT3 Activation <ul><li>Stat3 is activated by cytokines of the IL-6 family such as IL-6, IL-11, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M and cardiotropin I . </li></ul><ul><li>Stat3 is the major signal transducer downstream of gp130-like receptors . </li></ul><ul><li>Other extracellular signaling ligands such as IL-10 family members, epidermal growth factor (EGF), platelet derived growth factor (PDGF), hepa- tocyte growth factor (HGF), granulocyte colony- stimulating factor (G-CSF) and leptin have also known to activate Stat3. </li></ul>
  7. 9. Mechanism of Stat3 signaling <ul><li>Different tyrosine kinases (TKs) can induce Stat3 activation. Growth factors such as EGF bind to receptor tyrosine kinases (RTKs), followed by phosphorylation of Stat3 through activation of intermediary kineases of the SRC and JAK families. Cytokines such as IL-6 family members bind to gp130, a common receptor subunit, thereby JAK families and subsequent Stat3 are activated. Non-receptor TKs such as SRC and ABL can directly phophorylate Stat3 in the absence of ligand-dependent receptor signaling. In any pathway, two tyrosine phosphorylated Stat3 proteins form dimers, enter the nucleus and bind DNA to activate transcription of the target genes </li></ul>
  8. 10. <ul><li>Contribution of keratinocyte migration to both wound healing and anagen progression. (B) Stat3- dependent and -independent keratinocyte migration . </li></ul>
  9. 11. Class IIB(3)(b) latent cytoplasmic factors These families not present in fungi or plants, hinting at an important evolutionary divergence leading to animals.
  10. 12. STATs - a signal responsive TF family <ul><li>STATs: Signal Transducers and Activators of Transcription </li></ul><ul><ul><li>two functions given in the name </li></ul></ul><ul><li>1. Transducers for signals from many cytokines </li></ul><ul><ul><li>Broad spectrum of biological effects </li></ul></ul><ul><li>2. Transcriptional activators </li></ul><ul><ul><li>characteristic activation mechanism </li></ul></ul><ul><ul><li>activation at the cell membrane, response in the nucleus </li></ul></ul><ul><li>Rapid signal response </li></ul><ul><ul><li>The activation/deactivation cycle of STAT molecules is quite short, about 15 min for an individual molecule. </li></ul></ul>
  11. 13. Simple signalling pathway
  12. 14. REGULATION of Cell Signaling
  13. 15. The JAK-STAT signalling pathway <ul><li>Function: regulation of gene expression in response to cytokines </li></ul><ul><ul><li>1. cytokines bind and aggregate the cytokine receptors in the cell membrane </li></ul></ul><ul><ul><li>2. associated JAK-type tyrosine kinases are activated by aggregation and tyrosine-phosphorylates neighbouring-JAK (transphosphorylation) as well as the C-terminal tail of the receptor (multiple sites) </li></ul></ul><ul><ul><li>3. Tyr-phosphates recruit inactive STAT-factors in the cytoplasm which are bound through their SH2-domains </li></ul></ul><ul><ul><li>4. STATs become tyrosine-phosphorylated by JAK </li></ul></ul><ul><ul><li>5. phosphorylated STATs dissociate, dimerize (homo-/hetero-) and migrate to the nucleus </li></ul></ul><ul><ul><li>6. STAT-dimers bind DNA and activates target genes </li></ul></ul>
  14. 16. Canonical JAK–STAT pathway <ul><li>Sequential tyrosine phosphorylations </li></ul><ul><ul><li>Receptor dimerization allows transphosphorylation and activation of Janus kinases (JAKs). </li></ul></ul><ul><ul><li>This is followed by phosphorylation of receptor tails and the recruitment of the STAT proteins through their SH-2 domains. STAT tyrosine phosphorylation then occurs. </li></ul></ul><ul><ul><li>Dimerization of activated (tyrosine phosphorylated) STAT is followed by nuclear entry. </li></ul></ul>
  15. 17. IFN-response: two variants <ul><li>Signalling pathway first discovered in studies of interferon-response (IFN) </li></ul><ul><li>IFN  /  </li></ul><ul><ul><li>IFN  /   activation of Jak1+Tyk2  DNA-binding complexes (trimer: STAT1+STAT2+p48, together designated ISGF3)  activation of target genes with ISRE (IFN-stimulated response element) </li></ul></ul><ul><li>IFN  </li></ul><ul><ul><li>IFN   activation of Jak1+Jak2  DNA-binding complex (dimer: 2x STAT1)  activation of target genes having GAS elements (IFN  activated sequence) </li></ul></ul>
  16. 18. IFN-response: two variants
  17. 19. STAT-family members <ul><li>STAT1 - involved in IFN  /  - and IFN  -response </li></ul><ul><li>STAT2 - involved in IFN  /  -response </li></ul><ul><ul><li>Mainly acting as partner for STAT1/p48 </li></ul></ul><ul><li>STAT3 - involved in response to several cytokines including IL6. It activates several genes involved in acute phase response </li></ul><ul><ul><li>Important in growth regulation, embryonic development & organogenesis </li></ul></ul><ul><ul><li>Activation of STAT3 correlated with cell growth, link to cancer, bind c-Jun </li></ul></ul><ul><li>STAT4 - involved in IL12-response </li></ul><ul><li>STAT5a & 5b - involved in response to several cytokines including prolactin, IL-2, and regulates expression of milk proteins in breast tissue in response to prolactin </li></ul><ul><li>STAT6 - involved in IL4-response </li></ul><ul><li>non-mammalian family members (e.g. Drosophila ) </li></ul>
  18. 20. STAT-members SH2 Y
  19. 21. STAT-STAT interaction occurs through reciprocal phospho-Tyr - SH2 interactions <ul><li>SH2-domain </li></ul><ul><ul><li>SH2 = “Src-homology domain 2” </li></ul></ul><ul><ul><li>function: phospho-tyrosine binding </li></ul></ul><ul><ul><li>Three important functions in STATs: </li></ul></ul><ul><ul><ul><li>important for recruitment of STAT to receptor </li></ul></ul></ul><ul><ul><ul><li>important for interaction with the JAK kinase </li></ul></ul></ul><ul><ul><ul><li>important for dimerization of STATs to an active DNA-binding form </li></ul></ul></ul><ul><li>Tyr-701 </li></ul><ul><ul><li>conserved key Tyr residue located just C-terminal to SH2 </li></ul></ul><ul><ul><li>essensiell for dimerdannelse to an active DNA-binding form </li></ul></ul><ul><ul><li>function: Tyr P bindingssted for SH2 in partner </li></ul></ul>Y P Y P Y + Y
  20. 22. Dimerization via SH2-Tyr P Tyr P from the left monomer SH2 from the right monomer
  21. 23. STAT-members SH2 Y
  22. 24. STATs - structure and function <ul><li>Dimerization </li></ul><ul><ul><li>Reciprocal SH2- Tyr P interaction </li></ul></ul><ul><ul><li>Homodimers </li></ul></ul><ul><ul><ul><li>(STAT1) 2 </li></ul></ul></ul><ul><ul><li>Heterodimers </li></ul></ul><ul><ul><ul><li>STAT1-STAT2 </li></ul></ul></ul><ul><ul><ul><li>STAT1-STAT3 </li></ul></ul></ul><ul><li>DNA-binding domain </li></ul><ul><ul><li>DBD located in the middle of the protein </li></ul></ul><ul><ul><li>Unique motif - se next slide </li></ul></ul><ul><ul><li>All DBDs bind similar motifs in DNA </li></ul></ul><ul><ul><ul><li>symmetric inverted half sites </li></ul></ul></ul><ul><ul><ul><li>Only difference to STATs: preference for central nucleotide </li></ul></ul></ul>GAS= TTN 5-6 AA ISRE= AGTTTN 3 TTTCC
  23. 25. STAT-STRUCTURE <ul><li>Known structures </li></ul><ul><ul><li>[STAT1] 2 -DNA and [STAT3  ] 2 -DNA, as well as an N-terminal of STAT4 </li></ul></ul><ul><li>Characteristic feature : </li></ul><ul><ul><li>Symmetry-axis through DNA, each monomer contacts a separate half site </li></ul></ul><ul><ul><li>structure resembles NF  B and p53 (immunoglobuline fold). The dimer forms a C-shaped ”clamp” around DNA. </li></ul></ul><ul><ul><li>The dimer is kept together by reciprocal SH2- Tyr P interactions between the SH2 domain in one monomer and the phosphorylated Tyr in the other. </li></ul></ul><ul><ul><li>The SH2 domain in each monomer is closely linked to the core DBD and is itself close to DNA, and is assumed also to contribute to DNA-binding. </li></ul></ul><ul><ul><li>N-terminal coiled-coil region not close to DNA, probably involved in prot-prot interaction with flexible position </li></ul></ul>
  24. 26. 3D <ul><li>STAT domain structure and protein binding sites. </li></ul>
  25. 27. Promoter recognition and selectivity <ul><li>Mechanisms to achieve specific trx responses. </li></ul><ul><ul><li>Inverted repeat TTN 5–6 AA motif common. Binding specificity to individual elements based on evolved preferences for specific positions. </li></ul></ul><ul><ul><li>In the ISGF3 heterotrimeric complex, STAT1–STAT2 heterodimers bind to a third protein, p48/ISGF3  , a TF that recognizes the ISRE sequence. </li></ul></ul><ul><ul><li>STAT N-domains mediate dimer–dimer interactions allowing high-avidity binding to tandemly arranged low-affinity GAS elements. </li></ul></ul><ul><ul><li>Adjacent response elements bind to other TFs. Cooperativity and synergy. </li></ul></ul><ul><ul><li>STAT directly recruit co-activators that alter chromatin dynamics. </li></ul></ul>
  26. 28. Transactivation Domain(TAD) <ul><li>Transactivation domain </li></ul><ul><ul><li>C-terminal part of the protein, less conserved </li></ul></ul><ul><ul><li>variants generated by alternative splicing + proteolysis </li></ul></ul><ul><ul><li>STAT1  lacking the last 38aa has all functions retained except transactivation </li></ul></ul><ul><li>Regulation through TAD-modification </li></ul><ul><ul><li>Activity of TAD is regulated through Ser phosphorylation (LPMSP-motif) </li></ul></ul><ul><ul><ul><li>Ser727 in STAT1 </li></ul></ul></ul><ul><ul><li>Kinase not identified - candidates: p38, ERK, JNK </li></ul></ul><ul><ul><li>A role in recruitment of GTF/coactivator </li></ul></ul><ul><ul><li>Proteins identified that bind TAD in a Ser-dependent manner </li></ul></ul><ul><ul><ul><li>MCM5 </li></ul></ul></ul><ul><ul><ul><li>BRCA1 </li></ul></ul></ul><ul><li>TAD in STAT2 binds C/H-rich region of CBP </li></ul><ul><ul><li>STAT2 carries the principal TAD of the ISGF3-complex </li></ul></ul>
  27. 29. Other functional domains <ul><li>The N-domain is important for stabilizing interactions between STAT dimers, bound to tandemly arranged response elements </li></ul>
  28. 30. Psoriasis
  29. 31. Psoriasis <ul><li>Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation, abnormal differentiation of epidermal keratino- cytes, vascular proliferation, and leukocyte infiltration in the dermis and epidermis . </li></ul><ul><li>It has been considered that psoriasis results from complex, aberrant relationships between the skin and immune system as well as genetic predisposition and environmental factors </li></ul>
  30. 32. Psoriasis Clinical Presentation
  31. 33. Psoriasis as an immune disorder
  32. 34. T-Cell in Psoriasis
  33. 35. Immunomodulator(Alefacet) effect on Psorasis Area Score Index(PASI)
  34. 36. ANTI –Tumor Necrosis Factor (TNF) in Psoriasis
  35. 39. <ul><li>STAT3 links activated keratinocytes and immunocytes required for development of psoriasis( Sano S. et al, 2005; Nature Medicine 11:43-49 (. </li></ul>
  36. 41. Stat3 in keratinocytes(KC)
  37. 42. Prepsoriasis State
  38. 43. Prepsoriasis State
  39. 44. Immunopathology of Psoriasis
  40. 45. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis <ul><li>Epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3. </li></ul><ul><li>Transgenic mice with keratinocytes expressing a constitutively active Stat3 ( K5.Stat3C mice ) develop a skin phenotype either spontaneously, or in response to wounding, that closely resembles psoriasis. </li></ul><ul><li>Keratinocytes from K5.Stat3C mice show upregulation of several molecules linked to the pathogenesis of psoriasis. </li></ul><ul><li>In addition, the development of psoriatic lesions in K5.Stat3C mice requires cooperation between Stat3 activation in keratinocytes and activated T cells. </li></ul><ul><li>Finally, abrogation of Stat3 function by a decoy oligonucleotide inhibits the onset and reverses established psoriatic lesions in K5.Stat3C mice. Thus, targeting Stat3 may be potentially therapeutic in the treatment of psoriasis. </li></ul>
  41. 46. New Informations
  42. 48. Development of Psoriasis
  43. 49. Manipulation of Psorasis
  44. 50. Do Other Therapies Work Within This Framework? <ul><li>Anti–T-cell agents could affect Th17 cells as they would other T cells, but this needs to be clarified </li></ul><ul><li>Anti-TNF agents could decrease activity of Th17 cells or work directly on keratinocyte responses </li></ul>
  45. 52. Studies on Stat 3 in Psoriasis
  46. 53. Stat 3 in Psoriasis
  47. 56. New Prospectives &Directions
  48. 58. Tyrosine kinases
  49. 59. The JAK-family of tyrosine kinases <ul><li>Family members </li></ul><ul><ul><li>JAK1 (135 kDa) </li></ul></ul><ul><ul><li>JAK2 (130 kDa) </li></ul></ul><ul><ul><li>JAK3 (120 kDa) </li></ul></ul><ul><ul><li>Tyk2 (140 kDa) </li></ul></ul><ul><li>Common feature </li></ul><ul><ul><li>C-terminal kinase + pseudokinase </li></ul></ul><ul><ul><li>≠ RTK by lacking transmembrane domains and SH2, SH3, PTB, PH </li></ul></ul><ul><ul><li>several regions homologous between JAK-members </li></ul></ul><ul><ul><li>Associated with cytokine receptors (type in and II) </li></ul></ul><ul><li>Function </li></ul><ul><ul><li>Associated with cytokine receptors in non-stimulated cells in an inactive form </li></ul></ul>
  50. 60. The role of the kinases in the signalling pathway INF  -signalling INF  -signalling
  51. 61. The cytokine-receptor superfamily <ul><li>A receptor-family that mediates response to more than 30 different cytokines </li></ul><ul><li>Common feature: conserved extracellular ligand-binding domain </li></ul><ul><li>Are associated with tyrosine-kinases in the JAK-family </li></ul><ul><li>Ligand-binding  Receptor dimerization or oligomerization leads to JAK apposition  associated JAK Tyr kinases are activated  transphosphorylation of neighbour-JAKs  tyrosine-phosphorylation of C-terminal tail of receptors on multiple sites  several cellular substrate-proteins associate (including STATs)  multiple signalling pathways are activated </li></ul>
  52. 62. The role of the kinases in the signalling pathway INF  -signalling INF  -signalling
  53. 63. Specificity in response <ul><li>Specific cytokines activate distinct STATs and lead to a specific response - what mediate specificity? </li></ul><ul><ul><li>each cytokine activates a subgroup STAT </li></ul></ul><ul><ul><li>some cytokines activate only one specific STAT </li></ul></ul><ul><li>One contribution: the SH2 - receptor interaction specific for certain combinations </li></ul><ul><ul><li>swaps-experiments of SH2 between STATs change specificity </li></ul></ul><ul><ul><li>affinity of the SH2-receptor interaction is affected by the sequence context of the Tyr </li></ul></ul><ul><li>Another contribution: different STAT-dimers bind different response elements in the genome and turn on different genes </li></ul><ul><li>STAT1 knock-out mice illustrate biological specificity </li></ul><ul><ul><li>STAT1 -/- phenotype: total lack of IFN-response  highly sensitive to virus-infection </li></ul></ul>
  54. 64. Several signalling pathways linked <ul><li>STATs may also be Tyr-phosphorylated and hence activated by other receptor families </li></ul><ul><ul><li>receptor tyrosine kinases (RTKs) such as EGF-receptor may phosphorylate STATs </li></ul></ul><ul><ul><ul><li>EGF stimulation  activation of STAT1, STAT3 </li></ul></ul></ul><ul><ul><li>non-receptor tyrosine kinases such as Src and Abl may also phosphorylate STATs (?) </li></ul></ul><ul><ul><li>G-protein coupled 7TMS receptors such as angiotensine receptor (?) </li></ul></ul><ul><li>STAT may also be modified by Ser-phosphorylation </li></ul><ul><ul><li>DNA-binding reduced (STAT3) </li></ul></ul><ul><ul><li>Transactivationdomain Ser-phosphorylated (important for transactivation in STAT1 and STAT3) </li></ul></ul><ul><ul><li>Responsible kinases not identified - MAPkinases candidates, probably also others </li></ul></ul><ul><li>JAKs may activate other signalling pathways than STATs </li></ul><ul><ul><li>Tyr P will recruit several protein-substrates and lead to phosphorylation and activation of other signalling pathways </li></ul></ul><ul><ul><ul><li>e.g. JAK activation  activation of MAP-kinases </li></ul></ul></ul><ul><ul><ul><li>e.g. substrates: IRS-1, SHC, Grb2, HCP, Syp, Vav </li></ul></ul></ul>
  55. 65. Cross Talks <ul><li>Alternative inputs </li></ul><ul><ul><li>STATs may be Tyr-phosphorylated by RTKs </li></ul></ul><ul><li>Alternative outputs </li></ul><ul><ul><li>JAK may phosphorylate other targets and thus activate signal transduction pathways other than through STATs </li></ul></ul>P P P P P P P P JAK SH2 Cytokine receptor Y Y Y Y P P P Receptor tyrosinee kinase MAPK
  56. 66. Variations in mechanisms of STAT activation
  57. 67. SMAD family
  58. 68. SMAD-family - a logic resembling the STAT-family <ul><li>The Smad-factors mediate response to TGF  -related growth- and differentiation factors </li></ul><ul><li>STAT-related logic </li></ul><ul><ul><li>Membrane-bound receptors (such as the TGFß-receptor) are activated by binding of ligand (TGF  ). The receptors here are transmembrane serine/threonine-kinases </li></ul></ul><ul><ul><li>Activated kinases phosphorylate specific Smad-factors </li></ul></ul><ul><ul><li>phosphorylated Smad-factors associate with a common Smad-factor (Smad4) </li></ul></ul><ul><ul><li>The generated heteromeric complexes migrate to the nucleus as transcription factors </li></ul></ul>
  59. 69. TGF  effectors <ul><li>Latent cytoplasmic TFs activated by serine phosphorylation at their cognate receptors </li></ul><ul><li>This family transduces signals from the transforming growth factor-  (TGF-  ) superfamily of ligands . </li></ul>
  60. 70. Classification <ul><li>Smad-factors - design and classification </li></ul><ul><ul><li>Nine different Smad-factors identified in vertebrates </li></ul></ul><ul><ul><li>common conserved domains: N-terminalt MH1-domain (DBD) + C-terminalt MH2-domain </li></ul></ul><ul><li>Can be divided into three groups </li></ul><ul><ul><li>1. Receptor-activated Smad-factors - become phosphorylated by activated receptors in their C-terminal (SSXS) </li></ul></ul><ul><ul><li>2. common Smad-factors associated with activated Smad-factors and participate in several signalling pathways </li></ul></ul><ul><ul><li>3. Inhibitoriske Smad-factors </li></ul></ul>
  61. 71. SMAD-signalling pathway Effector SMADs (R-SMADs) C o-SMADs Repressor SMADs
  62. 72. Three groups of SMADs <ul><li>First group: The effector SMADs (also called the R-SMADs) become serine-phosphorylated in the C-terminal domain by the activated receptor . </li></ul><ul><ul><li>Smad1, Smad5, Smad8, and Smad9 become phosphorylated in response to bone morphogenetic morphogenetic protein (BMP) and growth and differentiation factor (GDF), and Smad2 and Smad3 become phosphorylated in response to the activin/nodal branch of the TGF-  pathway. </li></ul></ul><ul><li>Second group: regulatory or co-SMADs (common SMADs ). </li></ul><ul><ul><li>There are two regulatory SMADs: Smad4 and Smad4  (also called Smad10). </li></ul></ul><ul><ul><li>Smad4 binds to, and is essential for, the function of Smad1 and Smad2. The regulatory Smad4 binds to all effector SMADs in the formation of transcriptional complexes, but it does not appear to be required for nuclear translocation of the effector molecules. </li></ul></ul><ul><li>Third group: two inhibitory SMADs, Smad6 and Smad7 . </li></ul><ul><ul><li>provide negative regulation of the pathway by blocking Smad4 binding. </li></ul></ul>
  63. 73. SMAD-signalling pathway
  64. 74. Final steps - target gene activation <ul><li>Once an activated, serine-phosphorylated effector SMAD binds Smad4 and escapes the negative influences of Smad6 and Smad7, nuclear accumulation and regu-lation of specific target genes can occur. </li></ul><ul><ul><li>In most cases, SMADs require partner transcription factors with strong DNA binding capacity that determine the gene to be activated. The DNA binding is then strengthened by association with SMADs that on their own bind weakly to adjacent DNA sites. The SMADs furnish transcriptional activation capacity. </li></ul></ul><ul><ul><li>The specificity of response among different ligands can be partially explained by the choice of DNA binding partner proteins. For example, activin activation of SMADs results in combinations with FAST1 and a particular set of genes is activated. Signaling by BMP ligands results in association of activated SMADs with a DNA binding protein called OAZ. </li></ul></ul>
  65. 75. The Smad-factors activate their target genes in combination with other TFs
  66. 76. Message Home
  67. 77. THANK YOU